In Case You Missed It: A Recap of ACR Convergence 2020 by the Cleveland Clinic - Updates in Psoriatic Arthritis

0.50 CME

30 MINS

$0 FEE

SAVE

Overview

Provider Statement

This continuing medical education activity is provided by the Cleveland Clinic Foundation Center for Continuing Education. Cleveland Clinic

Educational Partner:

Support Statement

This activity is supported by educational grants from Janssen Scientific Affairs, LLC and Novartis Pharmaceuticals Corporation.

Activity Description

In this “In Case You Missed It” web activity, Drs. Len Calabrese and Elaine Husni will discuss exciting abstracts and key sessions on psoriatic arthritis from American College of Rheumatology (ACR) Convergence 2020.

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with rheumatological disorders and conditions.

Learning Objective

Upon successful completion of this educational activity, participants should be better able to assess the latest clinical evidence regarding new or emerging options for the management of patients with psoriatic arthritis and how they may be integrated into existing treatment algorithms.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Faculty

M. Elaine Husni, MD, MPH
Vice Chair of Rheumatology
Director, Arthritis and Musculoskeletal Center
Cleveland Clinic
Assistant Professor
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, OH

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Accreditation

Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 31, 2021 to January 30, 2022.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objective, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Cleveland Clinic Foundation Center for Continuing Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty members have indicated that they may have a relationship which, in the context of their contribution, could be perceived as a potential conflict of interest:

Activity Chair and Faculty report the following relationship(s)

Leonard H. Calabrese, DO
Consulting: Abbvie Pharmaceuticals, Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi Aventis, UCB
Teaching & Speaking: Abbvie Pharmaceuticals, Bristol-Myers Squibb, Crescendo, Genentech/Roche, Janssen, Novartis

M. Elaine Husni, MD, MPH
Consulting: Abbvie Pharmaceuticals, Amgen, Bristol-Myers Squibb Co., Genentech, Genzyme/Sanofi, Janssen, Lilly, Novartis Pharmaceuticals, Regeneron, UCB, Inc., WebMD
Membership on advisory committee or review panels: Abbvie Pharmaceuticals, Amgen, Bristol-Myers Squibb Co., Celgene Corporation, Genzyme/Sanofi, Janssen, Lilly, Novartis Pharmaceuticals, Pfizer, Inc., Regeneron
Teaching & Speaking: Novartis Pharmaceuticals, WebMD

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Cleveland Clinic Foundation Center for Continuing Education and Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Cleveland Clinic Foundation Center for Continuing Education and Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non—FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Cleveland Clinic Foundation Center for Continuing Education and Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Cleveland Clinic Foundation Center for Continuing Education or Vindico Medical Education. Neither Cleveland Clinic Foundation Center for Continuing Education, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.